(NASDAQ: ESPR) Esperion Therapeutics's forecast annual revenue growth rate of 11.71% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Esperion Therapeutics's revenue in 2025 is $303,802,000.On average, 11 Wall Street analysts forecast ESPR's revenue for 2025 to be $99,663,156,251, with the lowest ESPR revenue forecast at $81,530,194,554, and the highest ESPR revenue forecast at $111,979,704,525. On average, 11 Wall Street analysts forecast ESPR's revenue for 2026 to be $95,403,045,804, with the lowest ESPR revenue forecast at $79,428,826,943, and the highest ESPR revenue forecast at $122,998,138,337.
In 2027, ESPR is forecast to generate $104,028,454,611 in revenue, with the lowest revenue forecast at $68,520,362,313 and the highest revenue forecast at $139,163,607,946.